Find Helicobacter Pylori Infection Clinical Trials Near You
Efficacy and Safety of Linarazen Gluconate Capsules Combined With Amoxicillin (Dual-Drug Therapy) Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter Pylori Infection: A Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Controlled Study
Status: Recruiting
Location: See all (24) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This clinical trial aims to compare the efficacy of the dual therapy regimen of linralase glutarate capsules and amoxicillin versus the quadruple therapy regimen containing bismuth for the first-line eradication of Helicobacter pylori infection. The primary questions this trial aims to address include: 1. Whether the linalarenate glutarate capsule-amoxicillin dual-drug regimen is non-inferior to the bismuth-containing quadruple therapy, while simultaneously evaluating patient adherence and the incidence of adverse events in both treatment groups. Participants will: 1. Treatment group: Linaralate Glutarate Capsules (50 mg bid) + Amoxicillin (1 g tid), for a 14-day treatment course. 2. Control group: Esomeprazole 20 mg, twice daily (bid) + clarithromycin 0.5 g, twice daily (bid) + amoxicillin 1 g, twice daily (bid) + colloidal bismuth subcitrate 200 mg, twice daily (bid), for a 14-day treatment course. The primary endpoint is the Helicobacter pylori eradication rate 4 weeks after discontinuation of treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• (1) Adult patients aged 18-70 years, regardless of gender;
• (2) Patients diagnosed with Helicobacter pylori infection via 13C/14C-UBT;
• (3) Patients who have not previously undergone Helicobacter pylori eradication therapy;
• (4) Patients who have provided informed consent and voluntarily agreed to participate in this study.
Locations
Other Locations
China
Xuanwu Hospital, Capital Medical University
RECRUITING
Beijing
Yuanzhang@Mail.Tsinghua.Edu.Cn
RECRUITING
Beijing
Chongqing General Hospital
RECRUITING
Chongqing
The Sixth Affiliated Hospital of South China University of Technology
RECRUITING
Foshan
Fuzhou Traditional Chinese Medicine Hospital
RECRUITING
Fujian
Guangdong General Hospita
RECRUITING
Guangzhou
PLA General Hospital No. 962
RECRUITING
Ha’erbin
The First Affiliated Hospital of HarbinMedical University
RECRUITING
Ha’erbin
The First Affiliated Hospital of Henan University of Medicine
RECRUITING
Henan
Affiliated Hospital of Chengde Medical University
RECRUITING
Jiangxi
First Affiliated Hospital of Gannan Medical University
RECRUITING
Jiangxi
The First People's Hospital of Jingzhou
RECRUITING
Jingzhou
Longyan First Hospital
RECRUITING
Longyan
Shandong University of Traditional Chinese Medicine
RECRUITING
Shandong
The Second Hospital of Shandong University
RECRUITING
Shandong
General Hospital of Chengdu Military Command of PLA
RECRUITING
Sichuan
Sichuan Academy of Medical Sciences - Sichuan Provincial People's Hospital
RECRUITING
Sichuan
Taiyuan Iron and Steel (Group)
RECRUITING
Taiyuan
Wenzhou Central Hospital
RECRUITING
Wenzhou
Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITING
Xi'an
Xijing Hosipital of Digestive Disease
RECRUITING
Xi'an
Xuzhou Central Hospital
RECRUITING
Xuzhou
Henan Provincial People's Hospital
RECRUITING
Zhengzhou
The First Affiliated Hospital of ZhengzhouUniversity
RECRUITING
Zhengzhou
Contact Information
Primary
Yongquan Shi, Ph.D
von15991351319@163.com
86-029-84771535
Time Frame
Start Date:2026-10-01
Estimated Completion Date:2028-05-30
Participants
Target number of participants:448
Treatments
Experimental: Treatment group
Glutaric acid linalaric acid ester capsules (50 mg bid) + amoxicillin (1 g tid), for a 14-day course.